BeOne Medicines Q3 2026 Results: Net Income $385M, Up 208.2% YoY
BeOne Medicines Ltd. reported significant growth for the quarter ended September 30, 2026, with total revenues increasing to $1.89 billion from $1.41 billion in the prior year. Net income rose substantially to $384.7 million, or $3.28 per diluted ADS, driven by strong product sales and improved operating leverage despite increased R&D and SG&A spending.
- Key figure
- Net income $385M · +208.2% YoY